Atrial flutter with flecainide-induced 1:1 conduction at a rate <200 b.p.m. at rest: a case report

被引:2
作者
Dardas, Sotirios [1 ]
Khan, Asif [1 ]
机构
[1] Sherwood Forest Hosp NHS Fdn Trust, Kings Mill Hosp, Dept Cardiol, Mansfield Rd, Sutton In Ashfield NG17 4JL, Notts, England
关键词
Atrial fibrillation; Atrial flutter; 1:1 atrial flutter; Flecainide; Case report; FIBRILLATION;
D O I
10.1093/ehjcr/ytab396
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Class IC antiarrhythmic drug flecainide is commonly used in the management of atrial arrhythmias and in particular atrial fibrillation (AF). Although previously reported as a potential complication, atrial flutter (AFL) with 1:1 atrioventricular (AV) conduction is rare, with only few cases reported so far, most of which related to physical activity. In all previous reported cases, 1:1 conduction resulted in ventricular rates of >200 b.p.m. Case summary We report the case of a 60-year-old woman, who presented to our local emergency department with palpitations related to acute onset AF. The patient developed symptomatic 1:1 AFL with a rate of 192 b.p.m., shortly after administration of intravenous flecainide, which spontaneously converted back to AF and subsequently to sinus rhythm, with further administration of amiodarone and beta-blocker. Discussion The case raises awareness of this rare but potentially life-threatening complication to those using flecainide for pharmacological cardioversion of AF. QRS complex widening can be seen in the context of very rapid ventricular rates, posing additional diagnostic challenge, especially with rates of <200 b.p.m. Prescribing an AV nodal blocking agent, such as a beta-blocker, together with flecainide reduces significantly the risk of 1:1 conduction and should always be considered.
引用
收藏
页数:5
相关论文
共 12 条
[1]  
American College of Cardiology/American Heart Association Task Force on Practice Guidelines, 2014, J Am Coll Cardiol, V64, P1
[2]   1:1 atrial flutter induced by flecainide, whilst the patient was at rest [J].
Comelli, Ivan ;
Pigna, Federica ;
Cervellin, Gianfranco .
AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2018, 36 (11) :2131.e3-2131.e5
[3]  
Cosío FG, 2017, ARRHYTH ELECTROPHYSI, V6, P55, DOI [10.15420/aer.2017:5:2, 10.15420/aer.2017.5.2]
[4]   Use of Flecainide for the Treatment of Atrial Fibrillation [J].
Echt, Debra S. ;
Ruskin, Jeremy N. .
AMERICAN JOURNAL OF CARDIOLOGY, 2020, 125 (07) :1123-1133
[5]   PROARRHYTHMIA IN PATIENTS TREATED FOR ATRIAL-FIBRILLATION OR FLUTTER [J].
FALK, RH .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (02) :141-150
[6]  
HELDAL M, 1989, Tidsskrift for den Norske Laegeforening, V109, P2309
[7]  
Hindricks G., 2021, EUR HEART J, V42, P373, DOI [DOI 10.1093/eurheartj/ehaa945, 10.1093/eurheartj/ehaa612, DOI 10.1093/eurheartj/ehaa612]
[8]   ATRIAL FLUTTER WITH 1-1 A-V CONDUCTION [J].
MARKS, J .
ARCHIVES OF INTERNAL MEDICINE, 1957, 100 (06) :989-993
[9]   Radiofrequency ablation of "class IC atrial flutter" en patients with resistant atrial fibrillation [J].
Nabar, A ;
Rodriguez, LM ;
Timmermans, C ;
Smeets, JLRM ;
Wellens, HJJ .
AMERICAN JOURNAL OF CARDIOLOGY, 1999, 83 (05) :785-787
[10]   Intravenous magnesium in the management of rapid atrial fibrillation: A systematic review and meta-analysis [J].
Ramesh, Tushar ;
Lee, Paul Yong Kyu ;
Mitta, Monica ;
Allencherril, Joseph .
JOURNAL OF CARDIOLOGY, 2021, 78 (05) :375-381